A small Indianapolis company, Carnyx Therapeutics, says an experimental sleep pill made old rats sleep about 1.5 to 2 hours longer than rats that did not get it1. The company says most of that extra time was non-rapid eye movement sleep, or NREM, the non-dream part of the night that includes the deeper stages of sleep1. Carnyx also said it has hired Chris Brearley, a doctor with long experience in early drug testing, as its chief medical officer as it prepares to move toward tests in people1. The findings are from a company announcement, not a published paper, and so far apply only to animals.
What happened
Carnyx first announced the drug, which it calls CNYX-005, in a press release dated October 14, 20261. The same release was sent out again with an October 23 dateline2, and the longevity news site Longevity.Technology covered it on October 263. The hiring of Brearley was also logged on October 14 by the business database Fundz4.
The drug is taken by mouth and is still in preclinical development, the stage of lab and animal work that comes before any testing in people1. Carnyx describes itself as a preclinical-stage company developing new drugs for sleep and for retinitis pigmentosa, an inherited eye disease that slowly destroys vision1.
The evidence so far
According to the company, old rats given the drug slept roughly 1.5 to 2 hours more in total than a comparison group of untreated rats, and the increase was driven mainly by more NREM sleep1. The researchers tracked the stages of sleep with continuous EEG, a recording of the brain’s electrical activity1.
The company argues that the type of sleep matters as much as the amount. In its release, it says the deeper stages of NREM sleep are associated with growth, hormone release and tissue repair, and that sleep changes with age, with less deep NREM sleep and more broken-up nights1. Carnyx chief executive Patrick Gunning put the company’s aim this way:
“Our objective is not simply to induce sleep, but to investigate whether we can support restorative sleep physiology.”1
He added that the rise in NREM sleep “suggests CNYX-005 may influence sleep architecture, rather than simply increasing time asleep”1. Sleep architecture is the pattern of light, deep and dream sleep across a night.
What it does not show yet
The announcement leaves out much of what a reader would need to judge the result. As Longevity.Technology pointed out, the release does not say how many animals were used, what dose they received, or whether anything beyond sleep time was measured3. No paper or preprint has been released, so outside scientists cannot check the methods or the numbers.
Rats also sleep differently from people. Longevity.Technology noted that a result in old rats says little yet about what a pill would do for a person lying awake at 3 a.m.3 The site also observed that Gunning chose cautious words (“may influence”, “suggests”), which it said fits a rat study3.
Several basic questions are still open. The company has not said whether the extra sleep came with side effects, how long the effect lasted, or whether the treated rats did better on any measure of health or memory. Carnyx says it still has to establish the drug’s effectiveness, its safety and how the body absorbs and clears it1.
Who is behind it
All of the data come from Carnyx itself, and the sources do not say who paid for the rat study or how the company is funded. The release went out as a paid placement through PR Newswire1, and it carries the usual warning that its forward-looking statements may not prove accurate1.
The new chief medical officer, Chris Brearley, brings more than 30 years of experience in translational medicine (turning lab findings into treatments), clinical pharmacology and early drug development, including senior roles at Pfizer, Amgen and Serono1. The company says he has designed and overseen first-in-human studies, the very first tests of a new drug in people1. That is the step CNYX-005 would eventually need3.
“These findings provide important evidence supporting further evaluation of CNYX-005,” Brearley said in the release1. He said he looks forward to helping turn the findings into “a rigorous clinical development program”1.
Besides the sleep drug, Carnyx is developing a second candidate, CNYX-001, for retinitis pigmentosa1.
How it fits the field
Carnyx says the sleep drug grew out of research into peptides (short chains of protein building blocks) linked to sleep regulation and healthy aging, including research involving Epitalon, a peptide popular in some longevity circles1. The company stresses that CNYX-005 is a distinct drug candidate, which it is putting through standard drug-development work1. The release also notes that the U.S. Food and Drug Administration recently reviewed Epitalon and several other peptides as part of its evaluation of substances proposed for compounding pharmacies, which mix custom medicines1.
Gunning addressed that wider interest directly. “There is growing scientific and public interest in peptides and their potential applications in health and longevity, often ahead of rigorous clinical evidence,” he said, adding that the company aims to develop its candidate through formal testing, ending in trials in people1.
Sleep in old age is an active research area, and other rat studies show how results can depend on details. In a study published in April 2026 in Frontiers in Aging Neuroscience, researchers at Massachusetts General Hospital and Harvard Medical School recorded sleep in 44 old rats given either a ketogenic (very low-carb, high-fat) diet or a ketone supplement5. Both increased dream (REM) sleep in female rats, while old male rats showed no significant changes in sleep pattern, and the supplement actually reduced REM sleep in males during part of the day5. The authors describe sleep disruption in aging, such as more broken sleep, as something that can contribute to memory decline rather than just a side effect of it5. That study is unrelated to Carnyx, but it shows the kind of detail, such as the number of animals, their sex and the timing of effects, that Carnyx has not yet shared.
For people interested in longevity, a drug aimed at restoring some deep sleep is an idea worth following, Longevity.Technology wrote, while adding that Carnyx is “a long way” from showing such an effect in humans3.
What to watch next
The release gives no timeline for human trials and no description of what a first study in people would look like3. The next signs to watch for are:
- a published paper or conference presentation with the full rat data, including animal numbers, doses and any side effects;
- safety and dosing studies the company says it needs before human testing1;
- any filing to begin a first-in-human study, the kind of trial its new chief medical officer has run before1;
- news on how the company is funded, which the sources do not yet show.
Until then, the claim rests on a short company summary of one animal study.
